| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Avadel Pharmaceuticals plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.16 |
| 52 Week High | US$16.92 |
| 52 Week Low | US$13.90 |
| Beta | 0 |
| 1 Month Change | -10.04% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| AWK | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -7.6% | 4.7% | -0.3% |
| 1Y | n/a | -19.6% | 4.5% |
Return vs Industry: Insufficient data to determine how AWK performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AWK performed against the German Market.
Price Volatility
| AWK volatility | |
|---|---|
| AWK Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: AWK has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AWK's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 154 | Greg Divis | www.avadel.com |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc Fundamentals Summary
| AWK fundamental statistics | |
|---|---|
| Market cap | €1.39b |
| Earnings (TTM) | -€144.48m |
| Revenue (TTM) | €50.80m |
27.9x
P/S Ratio-9.8x
P/E RatioIs AWK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWK income statement (TTM) | |
|---|---|
| Revenue | US$55.14m |
| Cost of Revenue | US$2.37m |
| Gross Profit | US$52.77m |
| Other Expenses | US$209.61m |
| Earnings | -US$156.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 95.71% |
| Net Profit Margin | -284.42% |
| Debt/Equity Ratio | 43.8% |
How did AWK perform over the long term?
See historical performance and comparison